Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/56426
Title: [Dapagliflozin in the prevention and treatment of heart failure].
Other Titles: Dapagliflozina en la prevención y tratamiento de la insuficiencia cardiaca.
Authors: 
Keywords: 
Mesh: 
Issue Date: 14-Nov-2021
Citation: Semergen.2021;(47 Suppl 1):11-17
Abstract: To substantially reduce the risk of hospitalization and death among subjects with heart failure (HF) and reduced left ventricular ejection fraction, it is necessary to make a comprehensive approach of the different neurohormonal systems that are implied in its etiopathogenesis, including not only sympathetic nervous system, and renin-angiotensin system, but also vasoactive peptides and sodium-glucose transport protein 2. The DAPA-HF trial demonstrated that the addition of dapagliflozin to the standard treatment in HF with reduced left ventricular ejection fraction, markedly decreases the risk of cardiovascular death, HF hospitalization and overall death. In addition, dapagliflozin improves functional class and quality of life. Importantly, the prognostic benefit starts early after initiating treatment with dapagliflozin, regardless baseline therapy or the presence of diabetes. All these evidences make dapagliflozin as one of the mainstays of treatment for the management of HF with reduced left ventricular ejection fraction.
PMID: 34785155
URI: https://hdl.handle.net/20.500.12530/56426
Appears in Collections:Centros de Atención Primaria > Artículos

Files in This Item:
The file with the full text of this item is not available due to copyright restrictions or because there is no digital version. Authors can contact the head of the repository of their center to incorporate the corresponding file.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.